Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials, J Am Coll Cardiol, vol.68, issue.24, pp.2690-2707, 2016. ,
Monitoring clinical changes in patients with heart failure: a comparison of methods, Am Heart J, vol.150, issue.4, pp.707-722, 2005. ,
Ferric carboxymaltose in patients with heart failure and iron deficiency, N Engl J Med, vol.361, issue.25, pp.2436-2484, 2009. ,
Health-Related Quality of Life Outcomes in PARADIGM-HF, Circ Heart Fail, issue.8, p.10, 2017. ,
Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, vol.371, issue.11, pp.993-1004, 2014. ,
, N Engl J Med, 2019.
Spironolactone for heart failure with preserved ejection fraction, N Engl J Med, vol.370, issue.15, pp.1383-92, 2014. ,
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial, Circulation, vol.131, issue.1, pp.34-42, 2015. ,
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction, N Engl J Med, 2019. ,
Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION, Eur J Heart Fail, vol.21, issue.1, pp.63-70, 2019. ,
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity, Eur J Heart Fail, 2020. ,
The use of the win ratio in cardiovascular trials, 2020. ,